On Friday, Piper Sandler made a bullish move on Intra-Cellular Therapies (NASDAQ:ITCI), upgrading the stock from Neutral to Overweight and lifting the price target to $92 from $68.
The firm's analyst cited positive feedback from a survey of psychiatrists, which indicated that Intra-Cellular Therapies' drug Caplyta could achieve a market presence in treating major depressive disorder (MDD) comparable to that of AbbVie (NYSE:ABBV)'s Vraylar.
The survey, which included 25 psychiatrists, suggested that the patient and prescription volume for Caplyta as an adjunctive treatment for MDD could mirror the success observed with Vraylar.
This has led to a reassessment of Caplyta's peak sales potential in the United States, with projections nearing or surpassing $4 billion. Vraylar's sales are expected to exceed $3 billion this year, marking its second full year post-label expansion for MDD in December 2022.
The revised outlook for Caplyta's sales potential reflects a more favorable risk/reward profile for Intra-Cellular Therapies. The company may see significant operating leverage, as detailed in the analyst's discounted cash flow (DCF) analyses, referred to as Exhibits 1 and 2. However, there remains some uncertainty regarding the exclusivity period for Caplyta.
Intra-Cellular Therapies' stock upgrade and price target increase by Piper Sandler underscore a growing optimism in the drug's commercial prospects. The analyst's view is that Caplyta has the potential to become a major player in the MDD treatment market, with sales that could rival or even exceed those of established competitors.
In other recent news, Intra-Cellular Therapies has reported significant advancements in Q2 2024, announcing positive outcomes from two Phase III trials for its flagship product, CAPLYTA, in major depressive disorder (MDD). The company plans to submit a supplemental New Drug Application later in the year.
Net product sales for CAPLYTA reached $161.3 million, marking a 46% increase year-over-year, and the company raised its sales forecast for the product to between $650 million and $680 million for the full year.
Intra-Cellular Therapies' financial health remains robust, with over $1 billion in cash and investments, and the company is expanding its sales force to capture a larger market share in bipolar depression and potentially in MDD. The company is also exploring business development opportunities and evaluating the ex-U.S. market.
Despite not providing profitability guidance, Intra-Cellular Therapies is focused on becoming profitable. The company's pipeline includes promising drugs like ITI-1284, ITI-1020, ITI-333, and ITI-1549, and it plans to leverage the growing opportunity in treating bipolar depression in primary care settings.
InvestingPro Insights
In light of Piper Sandler's upgrade of Intra-Cellular Therapies, current InvestingPro data and tips offer further context for investors considering the stock's potential. Notably, Intra-Cellular Therapies holds a market capitalization of $7.65 billion, indicating a substantial size in the biopharmaceutical sector. Despite a negative P/E ratio of -84.14, reflecting its current lack of profitability, the company has demonstrated impressive revenue growth over the last twelve months as of Q2 2024, with a 54.31% increase. This growth could be a signal of Caplyta's rising market presence and future sales potential.
InvestingPro Tips add to the narrative, highlighting that Intra-Cellular Therapies has more cash than debt on its balance sheet and liquid assets exceed short-term obligations, providing financial stability as it scales up Caplyta's production and distribution. However, analysts have tempered expectations slightly, with nine analysts revising their earnings downwards for the upcoming period and not anticipating the company to be profitable this year. Yet, the company's strong return over the last five years suggests a resilient performance history.
For investors seeking to delve deeper into Intra-Cellular Therapies' financial health and future prospects, additional InvestingPro Tips are available at: https://www.investing.com/pro/ITCI, providing a comprehensive analysis of the company's performance and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.